Nontuberculous Mycobacterial Infection Global Market Report 2024

Nontuberculous Mycobacterial Infection Global Market Report 2024 – By Drug Class (Macrolides, Rifampin, Aminoglycoside, Other Drug Classes), By Route Of Administration (Oral, Parenteral, Other Routes), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies) – Market Size, Trends, And Global Forecast 2024-2033

Starting Price : $5000.00 | Pages : 175 | Published : January 2024 | Delivery Time: 2-3 business days | Format : pdf

Purchase Options
Request Sample
Request For Discount
FAQs

Need assistance or more information before the purchase?

Enquire Before Buying
Nontuberculous Mycobacterial Infection Global Market Report 2024

Proud Members Of

checkslacipN checkaoirsN checkscipN
Description Table Of Contents Tables & Figures Market Insights Related Reports

Nontuberculous Mycobacterial Infection Market Definition And Segments

A nontuberculous mycobacterial (NTM) infection is an infectious disease caused by various species of mycobacteria other than mycobacterium tuberculosis, which is responsible for tuberculosis (TB). The role of nontuberculous mycobacterial (NTM) infections is primarily related to their impact on human health and their interaction with the immune system.

The main classes of drugs for nontuberculous mycobacterial infection are macrolides, rifampin, aminoglycoside and others. Macrolides are a class of antibiotics that are commonly used to treat a variety of bacterial infections. They can be administered through oral, parenteral and other routes, which can be distributed by various channels such as hospital pharmacies, retail pharmacies and online pharmacies.

The nontuberculous mycobacterial infection market covered in this report is segmented –

1) By Drug Class: Macrolides, Rifampin, Aminoglycoside, Other Drug Classes

2) By Route Of Administration: Oral, Parenteral, Other Routes

3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

The nontuberculous mycobacterial infection market size has grown strongly in recent years. It will grow from $13.43 billion in 2023 to $14.25 billion in 2024 at a compound annual growth rate (CAGR) of 6.1%. The growth in the historic period can be attributed to improved diagnostics, aging population, cystic fibrosis awareness, immunosuppressive medications.

The nontuberculous mycobacterial infection market size is expected to see strong growth in the next few years. It will grow to $18.17 billion in 2028 at a compound annual growth rate (CAGR) of 6.3%. The growth in the forecast period can be attributed to antimicrobial drug development, increasing ntm awareness, advances in genetic research, telehealth and remote monitoring. Major trends in the forecast period include personalized treatment, regulatory focus, combination therapies, digital health tools.

Rising Prevalence Of Copd Fuels Growth In The Nontuberculous Mycobacterial Infection Market

The rising prevalence of chronic obstructive pulmonary disease (COPD) is expected to propel the growth of the nontuberculous mycobacterial infection market going forward. Chronic obstructive pulmonary disease (COPD) is a chronic respiratory condition characterized by persistent and often progressive lung airflow limitation. Nontuberculous mycobacterial (NTM) infections in patients with COPD are associated with a more significant decline in forced expiratory volume in one second (FEV1) and an increased exacerbation rate. COPD may weaken the immune system and damage the lung tissue, making it easier for NTM bacteria to infect the lungs. For instance, in March 2023, according to a report published by The Scottish Public Health Observatory (ScotPHO), a Scotland-based public health body, COPD rates began to climb between 2021 and 2022, with male rates increasing from 83.2 to 97.6 per 100,000 persons while female rates increased from 72.6 to 97.3. Therefore, the rising prevalence of chronic obstructive pulmonary disease (COPD) drives the growth of the nontuberculous mycobacterial infection market.

Increasing Prevalence Of Infectious Diseases To Drive The Growth Of Nontuberculous Mycobacterial Infection Market

The increasing prevalence of infectious diseases is expected to propel the growth of nontuberculous mycobacterial infection market going forward. Infectious diseases are illnesses caused by pathogenic microorganisms, such as bacteria, viruses, fungi, or parasites, that can be transmitted from one individual to another, leading to a variety of symptoms and health problems. The increasing prevalence of infectious diseases, including conditions that can lead to Nontuberculous Mycobacterial (NTM) infections, can potentially propel the growth of the NTM infection market by raising awareness of these infections, leading to more frequent diagnostic tests and early detection, increased research and development efforts for NTM treatments, and greater demand for therapies targeting NTM pathogens due to heightened healthcare focus on infectious diseases. For instance, as of December 2022, the United Nations International Children's Emergency Fund (UNICEF) reported that pneumonia was the leading infectious disease causing the death of over 700,000 children annually, equivalent to around 2,000 children per day. Therefore, the increasing prevalence of infectious diseases is driving the growth of nontuberculous mycobacterial infection market.

Major players in the nontuberculous mycobacterial infection market are Pfizer Inc., Johnson & Johnson, F. Hoffman La Roche AG, Merck & Co. Inc., AbbVie Inc., Bayer AG, Novartis AG, Sanofi S.A., Bristol Myers Squibb, AstraZeneca PLC, Abbott Laboratories, GlaxoSmithKline PLC, Takeda Pharmaceutical Company, Eli Lilly and Company, C.H. Boehringer Sohn AG & Co. KG, Teva Pharmaceutical Industries Ltd., Mylan N.V., Astellas Pharma Inc., Vertex Pharmaceuticals Inc., Sun Pharmaceutical Industries Ltd., Horizon Therapeutics PLC, Lupin Limited, BioMarin Pharmaceutical Inc., Ionis Pharmaceuticals Inc., Insmed Incorporated, Paratek Pharmaceuticals Inc., Spero Therapeutics Inc., Aradigm Corporation, Dauntless Pharmaceuticals Inc., Validus Pharmaceuticals LLC.

Challenges Posed By High Treatment Costs In The Non-Tuberculous Mycobacterial (NTM) Infection Market

The high treatment costs restrain the nontuberculous mycobacterial infection market's growth during the forecast period. High treatment costs can serve as a significant restraint in the management of non-tuberculous mycobacterial (NTM) infections. It creates a financial burden on patients, which can result in delayed or suboptimal treatment, potentially leading to worsened health outcomes. For instance, in 2023, according to the National Library of Medicine, a biomedical library, individuals with NTM (non-tuberculous mycobacterial) infection incurred notably higher costs compared to those in the control group. Specifically, for inpatient expenses, the average cost for NTM infection patients was $3934.55, whereas the control group's average cost stood at $2997.21. In terms of outpatient costs, individuals with NTM infection also experienced higher expenses, with an average cost of $2514.69, while the control group's average outpatient cost was $2115.04. Therefore, the high treatment costs has slowed the growth of the nontuberculous mycobacterial infection market.

Adoption Of Innovative Treatment Approvals In The Nontuberculous Mycobacterial Infection Market

Major companies operating in the nontuberculous mycobacterial infection market adopt new treatment approval practices to sustain their position in the market. For instance, in June 2021, Paratek Pharmaceuticals Inc., a US-based pharmaceutical company, received approval to expand NUZYRA's (omadacycline) indication for treating community-acquired bacterial pneumonia (CABP) in adults. NUZYRA is a modernized tetracycline specifically designed to overcome tetracycline resistance and exhibits activity across a spectrum of bacteria, including Gram-positive, Gram-negative, atypical and other drug-resistant strains. Further, in July 2022, the Food and Drug Administration, a US-based federal agency, granted Fast Track designation for NUZYRA to treat nontuberculous mycobacterial (NTM) lung disease due to MAC (Mycobacterium avium complex).

Qurient Collaborates With Tb Alliance To Develop Telacebec For Tuberculosis And Ntm Infections

In February 2023, Qurient Co. Ltd., a Korea-based biotech company, partnered with TB Alliance. This partnership aims to develop telacebec, a drug to treat tuberculosis and other nontuberculous mycobacteria (NTM) infections. TB Alliance will be granted the only global license for Telacebec through the agreement. This indicates that the TB Alliance will have the authority to continue working on the medicine and market it internationally. TB Alliance is a South Africa-based non-profit organization that develops and delivers economic TB medications.

North America was the largest region in the nontuberculous mycobacterial infection market in 2023. North America is expected to be the fastest-growing region in the forecast period. The regions covered in nontuberculous mycobacterial infection market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the nontuberculous mycobacterial infection market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, and Spain.

The nontuberculous mycobacterial infection market consists of revenues earned by entities by providing services such as treatment planning, antibiotic therapy, monitoring and follow-up. The market value includes the value of related goods sold by the service provider or included within the service offering. The nontuberculous mycobacterial infection market also includes sales of azithromycin, rifampin, ethambutol, streptomycin, medical equipment, pulmonary rehabilitation and supportive care products. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

The nontuberculous mycobacterial infection market research report is one of a series of new reports from The Business Research Company that provides nontuberculous mycobacterial infection market statistics, including nontuberculous mycobacterial infection industry global market size, regional shares, competitors with a nontuberculous mycobacterial infection market share, detailed nontuberculous mycobacterial infection market segments, market trends and opportunities and any further data you may need to thrive in the nontuberculous mycobacterial infection industry. This nontuberculous mycobacterial infection market research report delivers a complete perspective on everything you need, with an in-depth analysis of the current and future scenarios of the industry.

Nontuberculous Mycobacterial Infection Market Report Scope
Report AttributeDetails
Market Size Value In 2024 $14.25 billion
Revenue Forecast In 2033 $18.17 billion
Growth Rate CAGR of 6.3% from 2024 to 2033
Base Year For Estimation 2023
Actual Estimates/Historical Data 2018-2023
Forecast Period 2024 - 2028 - 2033
Market Representation Revenue in USD Billion and CAGR from 2024 to 2033
Segments Covered 1) By Drug Class: Macrolides, Rifampin, Aminoglycoside, Other Drug Classes
2) By Route Of Administration: Oral, Parenteral, Other Routes
3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
Regional Scope Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Country Scope Australia; China; India; Indonesia; Japan; South Korea; Bangladesh; Thailand; Vietnam; Malaysia; Singapore; Philippines; Hong Kong; New Zealand; USA; Canada; Mexico; Brazil; Chile; Argentina; Colombia; Peru; France; Germany; UK; Austria; Belgium; Denmark; Finland; Ireland; Italy; Netherlands; Norway; Portugal; Spain; Sweden; Switzerland; Russia; Czech Republic; Poland; Romania; Ukraine; Saudi Arabia; Israel; Iran; Turkey; UAE; Egypt; Nigeria; South Africa
Key Companies Profiled Pfizer Inc.; Johnson & Johnson; F. Hoffman La Roche AG; Merck & Co. Inc.; AbbVie Inc.; Bayer AG; Novartis AG; Sanofi S.A.; Bristol Myers Squibb; AstraZeneca plc; Abbott Laboratories; GlaxoSmithKline plc; Takeda Pharmaceutical Company; Eli Lilly and Company; C.H. Boehringer Sohn AG & Co. KG; Teva Pharmaceutical Industries Ltd.; Mylan N.V.; Astellas Pharma Inc.; Vertex Pharmaceuticals Inc.; Sun Pharmaceutical Industries Ltd.; Horizon Therapeutics Plc; Lupin Limited; BioMarin Pharmaceutical Inc.; Ionis Pharmaceuticals Inc.; Insmed Incorporated; Paratek Pharmaceuticals Inc.; Spero Therapeutics Inc.; Aradigm Corporation; Dauntless Pharmaceuticals Inc.; Validus Pharmaceuticals LLC
Customization ScopeRequest for Sample
Pricing And Purchase OptionsExplore Purchase Options

    Table Of Contents

    1. Executive Summary

    2. Nontuberculous Mycobacterial Infection Market Characteristics

    3. Nontuberculous Mycobacterial Infection Market Trends And Strategies

    4. Nontuberculous Mycobacterial Infection Market - Macro Economic Scenario

    4.1. Impact Of High Inflation On The Market

    4.2. Ukraine-Russia War Impact On The Market

    4.3. COVID-19 Impact On The Market

    5. Global Nontuberculous Mycobacterial Infection Market Size and Growth

    5.1. Global Nontuberculous Mycobacterial Infection Market Drivers and Restraints

    5.1.1. Drivers Of The Market

    5.1.2. Restraints Of The Market

    5.2. Global Nontuberculous Mycobacterial Infection Historic Market Size and Growth, 2018 - 2023, Value ($ Billion)

    5.3. Global Nontuberculous Mycobacterial Infection Forecast Market Size and Growth, 2023 - 2028, 2033F, Value ($ Billion)

    6. Nontuberculous Mycobacterial Infection Market Segmentation

    6.1. Global Nontuberculous Mycobacterial Infection Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    Macrolides

    Rifampin

    Aminoglycoside

    Other Drug Classes

    6.2. Global Nontuberculous Mycobacterial Infection Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    Oral

    Parenteral

    Other Routes

    6.3. Global Nontuberculous Mycobacterial Infection Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    Hospital Pharmacies

    Retail Pharmacies

    Online Pharmacies

    7. Nontuberculous Mycobacterial Infection Market Regional And Country Analysis

    7.1. Global Nontuberculous Mycobacterial Infection Market, Split By Region, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    7.2. Global Nontuberculous Mycobacterial Infection Market, Split By Country, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    8. Asia-Pacific Nontuberculous Mycobacterial Infection Market  

    8.1. Asia-Pacific Nontuberculous Mycobacterial Infection Market Overview  

    Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies

    8.2. Asia-Pacific Nontuberculous Mycobacterial Infection Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    8.3. Asia-Pacific Nontuberculous Mycobacterial Infection Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    8.4. Asia-Pacific Nontuberculous Mycobacterial Infection Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    9. China Nontuberculous Mycobacterial Infection Market  

    9.1. China Nontuberculous Mycobacterial Infection Market Overview  

    9.2. China Nontuberculous Mycobacterial Infection Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion

    9.3. China Nontuberculous Mycobacterial Infection Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion

    9.4. China Nontuberculous Mycobacterial Infection Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion

    10. India Nontuberculous Mycobacterial Infection Market  

    10.1. India Nontuberculous Mycobacterial Infection Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    10.2. India Nontuberculous Mycobacterial Infection Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    10.3. India Nontuberculous Mycobacterial Infection Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    11. Japan Nontuberculous Mycobacterial Infection Market  

    11.1. Japan Nontuberculous Mycobacterial Infection Market Overview  

    11.2. Japan Nontuberculous Mycobacterial Infection Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    11.3. Japan Nontuberculous Mycobacterial Infection Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    11.4. Japan Nontuberculous Mycobacterial Infection Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    12. Australia Nontuberculous Mycobacterial Infection Market  

    12.1. Australia Nontuberculous Mycobacterial Infection Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    12.2. Australia Nontuberculous Mycobacterial Infection Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    12.3. Australia Nontuberculous Mycobacterial Infection Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    13. Indonesia Nontuberculous Mycobacterial Infection Market  

    13.1. Indonesia Nontuberculous Mycobacterial Infection Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    13.2. Indonesia Nontuberculous Mycobacterial Infection Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    13.3. Indonesia Nontuberculous Mycobacterial Infection Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    14. South Korea Nontuberculous Mycobacterial Infection Market  

    14.1. South Korea Nontuberculous Mycobacterial Infection Market Overview  

    14.2. South Korea Nontuberculous Mycobacterial Infection Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    14.3. South Korea Nontuberculous Mycobacterial Infection Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    14.4. South Korea Nontuberculous Mycobacterial Infection Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    15. Western Europe Nontuberculous Mycobacterial Infection Market  

    15.1. Western Europe Nontuberculous Mycobacterial Infection Market Overview

    15.2. Western Europe Nontuberculous Mycobacterial Infection Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    15.3. Western Europe Nontuberculous Mycobacterial Infection Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    15.4. Western Europe Nontuberculous Mycobacterial Infection Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    16. UK Nontuberculous Mycobacterial Infection Market  

    16.1. UK Nontuberculous Mycobacterial Infection Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    16.2. UK Nontuberculous Mycobacterial Infection Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    16.3. UK Nontuberculous Mycobacterial Infection Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    17. Germany Nontuberculous Mycobacterial Infection Market  

    17.1. Germany Nontuberculous Mycobacterial Infection Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    17.2. Germany Nontuberculous Mycobacterial Infection Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    17.3. Germany Nontuberculous Mycobacterial Infection Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    18. France Nontuberculous Mycobacterial Infection Market  

    18.5. France Nontuberculous Mycobacterial Infection Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    18.6. France Nontuberculous Mycobacterial Infection Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    18.7. France Nontuberculous Mycobacterial Infection Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    19. Italy Nontuberculous Mycobacterial Infection Market  

    19.9. Italy Nontuberculous Mycobacterial Infection Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    19.10. Italy Nontuberculous Mycobacterial Infection Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    19.11. Italy Nontuberculous Mycobacterial Infection Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    20. Spain Nontuberculous Mycobacterial Infection Market  

    20.13. Spain Nontuberculous Mycobacterial Infection Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    20.14. Spain Nontuberculous Mycobacterial Infection Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    20.15. Spain Nontuberculous Mycobacterial Infection Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    21. Eastern Europe Nontuberculous Mycobacterial Infection Market  

    21.1. Eastern Europe Nontuberculous Mycobacterial Infection Market Overview

    21.2. Eastern Europe Nontuberculous Mycobacterial Infection Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    21.3. Eastern Europe Nontuberculous Mycobacterial Infection Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    21.4. Eastern Europe Nontuberculous Mycobacterial Infection Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    22. Russia Nontuberculous Mycobacterial Infection Market  

    22.1. Russia Nontuberculous Mycobacterial Infection Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    22.2. Russia Nontuberculous Mycobacterial Infection Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    22.3. Russia Nontuberculous Mycobacterial Infection Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    23. North America Nontuberculous Mycobacterial Infection Market  

    23.1. North America Nontuberculous Mycobacterial Infection Market Overview

    23.2. North America Nontuberculous Mycobacterial Infection Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    23.3. North America Nontuberculous Mycobacterial Infection Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    23.4. North America Nontuberculous Mycobacterial Infection Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    24. USA Nontuberculous Mycobacterial Infection Market  

    24.1. USA Nontuberculous Mycobacterial Infection Market Overview

    24.2. USA Nontuberculous Mycobacterial Infection Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    24.3. USA Nontuberculous Mycobacterial Infection Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    24.4. USA Nontuberculous Mycobacterial Infection Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    25. Canada Nontuberculous Mycobacterial Infection Market  

    25.1. Canada Nontuberculous Mycobacterial Infection Market Overview

    25.2. Canada Nontuberculous Mycobacterial Infection Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    25.3. Canada Nontuberculous Mycobacterial Infection Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    25.4. Canada Nontuberculous Mycobacterial Infection Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    26. South America Nontuberculous Mycobacterial Infection Market  

    26.1. South America Nontuberculous Mycobacterial Infection Market Overview

    26.2. South America Nontuberculous Mycobacterial Infection Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    26.3. South America Nontuberculous Mycobacterial Infection Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    26.4. South America Nontuberculous Mycobacterial Infection Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    27. Brazil Nontuberculous Mycobacterial Infection Market  

    27.1. Brazil Nontuberculous Mycobacterial Infection Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    27.2. Brazil Nontuberculous Mycobacterial Infection Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    27.3. Brazil Nontuberculous Mycobacterial Infection Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    28. Middle East Nontuberculous Mycobacterial Infection Market  

    28.1. Middle East Nontuberculous Mycobacterial Infection Market Overview

    28.2. Middle East Nontuberculous Mycobacterial Infection Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    28.3. Middle East Nontuberculous Mycobacterial Infection Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    28.4. Middle East Nontuberculous Mycobacterial Infection Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    29. Africa Nontuberculous Mycobacterial Infection Market  

    29.1. Africa Nontuberculous Mycobacterial Infection Market Overview

    29.2. Africa Nontuberculous Mycobacterial Infection Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    29.3. Africa Nontuberculous Mycobacterial Infection Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    29.4. Africa Nontuberculous Mycobacterial Infection Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    30. Nontuberculous Mycobacterial Infection Market Competitive Landscape And Company Profiles

    30.1. Nontuberculous Mycobacterial Infection Market Competitive Landscape

    30.2. Nontuberculous Mycobacterial Infection Market Company Profiles

    30.2.1. Pfizer Inc.

    30.2.1.1. Overview

    30.2.1.2. Products and Services

    30.2.1.3. Strategy

    30.2.1.4. Financial Performance

    30.2.2. Johnson & Johnson

    30.2.2.1. Overview

    30.2.2.2. Products and Services

    30.2.2.3. Strategy

    30.2.2.4. Financial Performance

    30.2.3. F. Hoffman La Roche AG

    30.2.3.1. Overview

    30.2.3.2. Products and Services

    30.2.3.3. Strategy

    30.2.3.4. Financial Performance

    30.2.4. Merck & Co. Inc.

    30.2.4.1. Overview

    30.2.4.2. Products and Services

    30.2.4.3. Strategy

    30.2.4.4. Financial Performance

    30.2.5. AbbVie Inc.

    30.2.5.1. Overview

    30.2.5.2. Products and Services

    30.2.5.3. Strategy

    30.2.5.4. Financial Performance

    31. Nontuberculous Mycobacterial Infection Market Other Major And Innovative Companies

    31.1. Bayer AG

    31.2. Novartis AG

    31.3. Sanofi S.A.

    31.4. Bristol Myers Squibb

    31.5. AstraZeneca plc

    31.6. Abbott Laboratories

    31.7. GlaxoSmithKline plc

    31.8. Takeda Pharmaceutical Company

    31.9. Eli Lilly and Company

    31.10. C.H. Boehringer Sohn AG & Co. KG

    31.11. Teva Pharmaceutical Industries Ltd.

    31.12. Mylan N.V.

    31.13. Astellas Pharma Inc.

    31.14. Vertex Pharmaceuticals Inc.

    31.15. Sun Pharmaceutical Industries Ltd.

    32. Global Nontuberculous Mycobacterial Infection Market Competitive Benchmarking

    33. Global Nontuberculous Mycobacterial Infection Market Competitive Dashboard

    34. Key Mergers And Acquisitions In The Nontuberculous Mycobacterial Infection Market

    35. Nontuberculous Mycobacterial Infection Market Future Outlook and Potential Analysis

    35.1 Nontuberculous Mycobacterial Infection Market In 2028 - Countries Offering Most New Opportunities

    35.2 Nontuberculous Mycobacterial Infection Market In 2028 - Segments Offering Most New Opportunities

    35.3 Nontuberculous Mycobacterial Infection Market In 2028 - Growth Strategies

    35.3.1 Market Trend Based Strategies

    35.3.2 Competitor Strategies

    36. Appendix

    36.1. Abbreviations

    36.2. Currencies

    36.3. Historic And Forecast Inflation Rates

    36.4. Research Inquiries

    36.5. The Business Research Company

    36.6. Copyright And Disclaimer

List Of Tables

    Table 1: Global Historic Market Growth, 2018-2023, $ Billion
  • Table 2: Global Forecast Market Growth, 2023-2028F, 2033F, $ Billion
  • Table 3: Global Nontuberculous Mycobacterial Infection Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 4: Global Nontuberculous Mycobacterial Infection Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 5: Global Nontuberculous Mycobacterial Infection Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 6: Global Nontuberculous Mycobacterial Infection Market, Split By Region, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 7: Global Nontuberculous Mycobacterial Infection Market, Split By Country, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 8: Asia-Pacific, Nontuberculous Mycobacterial Infection Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 9: Asia-Pacific, Nontuberculous Mycobacterial Infection Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 10: Asia-Pacific, Nontuberculous Mycobacterial Infection Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 11: China, Nontuberculous Mycobacterial Infection Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 12: China, Nontuberculous Mycobacterial Infection Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 13: China, Nontuberculous Mycobacterial Infection Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 14: India, Nontuberculous Mycobacterial Infection Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 15: India, Nontuberculous Mycobacterial Infection Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 16: India, Nontuberculous Mycobacterial Infection Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 17: Japan, Nontuberculous Mycobacterial Infection Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 18: Japan, Nontuberculous Mycobacterial Infection Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 19: Japan, Nontuberculous Mycobacterial Infection Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 20: Australia, Nontuberculous Mycobacterial Infection Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 21: Australia, Nontuberculous Mycobacterial Infection Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 22: Australia, Nontuberculous Mycobacterial Infection Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 23: Indonesia, Nontuberculous Mycobacterial Infection Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 24: Indonesia, Nontuberculous Mycobacterial Infection Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 25: Indonesia, Nontuberculous Mycobacterial Infection Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 26: South Korea, Nontuberculous Mycobacterial Infection Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 27: South Korea, Nontuberculous Mycobacterial Infection Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 28: South Korea, Nontuberculous Mycobacterial Infection Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 29: Western Europe, Nontuberculous Mycobacterial Infection Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 30: Western Europe, Nontuberculous Mycobacterial Infection Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 31: Western Europe, Nontuberculous Mycobacterial Infection Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 32: UK, Nontuberculous Mycobacterial Infection Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 33: UK, Nontuberculous Mycobacterial Infection Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 34: UK, Nontuberculous Mycobacterial Infection Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 35: Germany, Nontuberculous Mycobacterial Infection Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 36: Germany, Nontuberculous Mycobacterial Infection Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 37: Germany, Nontuberculous Mycobacterial Infection Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 38: France, Nontuberculous Mycobacterial Infection Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 39: France, Nontuberculous Mycobacterial Infection Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 40: France, Nontuberculous Mycobacterial Infection Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 41: Italy, Nontuberculous Mycobacterial Infection Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 42: Italy, Nontuberculous Mycobacterial Infection Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 43: Italy, Nontuberculous Mycobacterial Infection Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 44: Spain, Nontuberculous Mycobacterial Infection Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 45: Spain, Nontuberculous Mycobacterial Infection Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 46: Spain, Nontuberculous Mycobacterial Infection Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 47: Eastern Europe, Nontuberculous Mycobacterial Infection Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 48: Eastern Europe, Nontuberculous Mycobacterial Infection Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 49: Eastern Europe, Nontuberculous Mycobacterial Infection Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 50: Russia, Nontuberculous Mycobacterial Infection Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 51: Russia, Nontuberculous Mycobacterial Infection Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 52: Russia, Nontuberculous Mycobacterial Infection Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 53: North America, Nontuberculous Mycobacterial Infection Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 54: North America, Nontuberculous Mycobacterial Infection Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 55: North America, Nontuberculous Mycobacterial Infection Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 56: USA, Nontuberculous Mycobacterial Infection Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 57: USA, Nontuberculous Mycobacterial Infection Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 58: USA, Nontuberculous Mycobacterial Infection Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 59: Canada, Nontuberculous Mycobacterial Infection Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 60: Canada, Nontuberculous Mycobacterial Infection Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 61: Canada, Nontuberculous Mycobacterial Infection Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 62: South America, Nontuberculous Mycobacterial Infection Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 63: South America, Nontuberculous Mycobacterial Infection Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 64: South America, Nontuberculous Mycobacterial Infection Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 65: Brazil, Nontuberculous Mycobacterial Infection Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 66: Brazil, Nontuberculous Mycobacterial Infection Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 67: Brazil, Nontuberculous Mycobacterial Infection Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 68: Middle East, Nontuberculous Mycobacterial Infection Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 69: Middle East, Nontuberculous Mycobacterial Infection Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 70: Middle East, Nontuberculous Mycobacterial Infection Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 71: Africa, Nontuberculous Mycobacterial Infection Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 72: Africa, Nontuberculous Mycobacterial Infection Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 73: Africa, Nontuberculous Mycobacterial Infection Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 74: Pfizer Inc. Financial Performance
  • Table 75: Johnson & Johnson Financial Performance
  • Table 76: F. Hoffman La Roche AG Financial Performance
  • Table 77: Merck & Co. Inc. Financial Performance
  • Table 78: AbbVie Inc. Financial Performance

List Of Figures

    Figure 1: Global Historic Market Growth, 2018-2023, $ Billion
  • Figure 2: Global Forecast Market Growth, 2023-2028F, 2033F, $ Billion
  • Figure 3: Global Nontuberculous Mycobacterial Infection Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 4: Global Nontuberculous Mycobacterial Infection Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 5: Global Nontuberculous Mycobacterial Infection Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 6: Global Nontuberculous Mycobacterial Infection Market, Split By Region, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 7: Global Nontuberculous Mycobacterial Infection Market, Split By Country, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 8: Asia-Pacific, Nontuberculous Mycobacterial Infection Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 9: Asia-Pacific, Nontuberculous Mycobacterial Infection Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 10: Asia-Pacific, Nontuberculous Mycobacterial Infection Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 11: China, Nontuberculous Mycobacterial Infection Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 12: China, Nontuberculous Mycobacterial Infection Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 13: China, Nontuberculous Mycobacterial Infection Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 14: India, Nontuberculous Mycobacterial Infection Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 15: India, Nontuberculous Mycobacterial Infection Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 16: India, Nontuberculous Mycobacterial Infection Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 17: Japan, Nontuberculous Mycobacterial Infection Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 18: Japan, Nontuberculous Mycobacterial Infection Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 19: Japan, Nontuberculous Mycobacterial Infection Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 20: Australia, Nontuberculous Mycobacterial Infection Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 21: Australia, Nontuberculous Mycobacterial Infection Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 22: Australia, Nontuberculous Mycobacterial Infection Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 23: Indonesia, Nontuberculous Mycobacterial Infection Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 24: Indonesia, Nontuberculous Mycobacterial Infection Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 25: Indonesia, Nontuberculous Mycobacterial Infection Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 26: South Korea, Nontuberculous Mycobacterial Infection Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 27: South Korea, Nontuberculous Mycobacterial Infection Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 28: South Korea, Nontuberculous Mycobacterial Infection Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 29: Western Europe, Nontuberculous Mycobacterial Infection Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 30: Western Europe, Nontuberculous Mycobacterial Infection Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 31: Western Europe, Nontuberculous Mycobacterial Infection Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 32: UK, Nontuberculous Mycobacterial Infection Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 33: UK, Nontuberculous Mycobacterial Infection Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 34: UK, Nontuberculous Mycobacterial Infection Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 35: Germany, Nontuberculous Mycobacterial Infection Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 36: Germany, Nontuberculous Mycobacterial Infection Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 37: Germany, Nontuberculous Mycobacterial Infection Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 38: France, Nontuberculous Mycobacterial Infection Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 39: France, Nontuberculous Mycobacterial Infection Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 40: France, Nontuberculous Mycobacterial Infection Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 41: Italy, Nontuberculous Mycobacterial Infection Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 42: Italy, Nontuberculous Mycobacterial Infection Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 43: Italy, Nontuberculous Mycobacterial Infection Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 44: Spain, Nontuberculous Mycobacterial Infection Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 45: Spain, Nontuberculous Mycobacterial Infection Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 46: Spain, Nontuberculous Mycobacterial Infection Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 47: Eastern Europe, Nontuberculous Mycobacterial Infection Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 48: Eastern Europe, Nontuberculous Mycobacterial Infection Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 49: Eastern Europe, Nontuberculous Mycobacterial Infection Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 50: Russia, Nontuberculous Mycobacterial Infection Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 51: Russia, Nontuberculous Mycobacterial Infection Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 52: Russia, Nontuberculous Mycobacterial Infection Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 53: North America, Nontuberculous Mycobacterial Infection Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 54: North America, Nontuberculous Mycobacterial Infection Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 55: North America, Nontuberculous Mycobacterial Infection Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 56: USA, Nontuberculous Mycobacterial Infection Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 57: USA, Nontuberculous Mycobacterial Infection Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 58: USA, Nontuberculous Mycobacterial Infection Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 59: Canada, Nontuberculous Mycobacterial Infection Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 60: Canada, Nontuberculous Mycobacterial Infection Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 61: Canada, Nontuberculous Mycobacterial Infection Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 62: South America, Nontuberculous Mycobacterial Infection Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 63: South America, Nontuberculous Mycobacterial Infection Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 64: South America, Nontuberculous Mycobacterial Infection Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 65: Brazil, Nontuberculous Mycobacterial Infection Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 66: Brazil, Nontuberculous Mycobacterial Infection Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 67: Brazil, Nontuberculous Mycobacterial Infection Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 68: Middle East, Nontuberculous Mycobacterial Infection Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 69: Middle East, Nontuberculous Mycobacterial Infection Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 70: Middle East, Nontuberculous Mycobacterial Infection Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 71: Africa, Nontuberculous Mycobacterial Infection Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 72: Africa, Nontuberculous Mycobacterial Infection Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 73: Africa, Nontuberculous Mycobacterial Infection Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 74: Pfizer Inc. Financial Performance
  • Figure 75: Johnson & Johnson Financial Performance
  • Figure 76: F. Hoffman La Roche AG Financial Performance
  • Figure 77: Merck & Co. Inc. Financial Performance
  • Figure 78: AbbVie Inc. Financial Performance
Forecasting Till 2030: Opportunities And Strategies In The Global Value Based Care Payment Market – Includes Value Based Care Payment Market Analysis
Read More
How Will The Nuclear Medicine Market Grow In 2022?
Read More
What Is The Pediatric Imaging Market Overview In 2022?
Read More
Latest Healthcare Technology Management Market Growth Study 2022-2026 By The Business Research Company
Read More
The Business Research Company offers the hospital acquired infection control market research report 2022 with industry size, share, segments and market growth
Read More
The Business Research Company offers the multiplex assays market research report 2022 with industry size, share, segments and market growth
Read More
The Business Research Company offers the healthcare it consulting market research report 2022 with industry size, share, segments and market growth
Read More
The Business Research Company offers the renal biomarkers market research report 2022 with industry size, share, segments and market growth
Read More
Tuberculosis Diagnostics Global Market Report 2024 – By Test Type (Radiographic Tests, Nucleic Acid Testing, Cytokine Detection Tests, Drug Resistance Tests, Skin Test / Mantoux Test (TST), Blood/Serology Test, Smear Microscopy Tests, Cell Culture-Based Tests, Other Test Types), By Disease Stage (Latent Tuberculosis, Active Tuberculosis), By End-User (Hospitals And Diagnostic Laboratories, Physician’s Office Laboratories, Reference Laboratories, Academics And Research Facilities) – Market Size, Trends, And Global Forecast 2024-2033
View Report
Cough And Cold Preparations Global Market Report 2024 – By Drug Type (Antihistamines, Expectorants, Bronchodilators, Decongestants, Antibiotics, Other Drug Types), By Dosage Type (Oral Syrups, Tablets/Pills, Nasal Drops, Lozenges, Other Dosage Types), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Drug Stores, Other Distribution Channels) – Market Size, Trends, And Global Forecast 2024-2033
View Report
Chronic Cough Global Market Report 2024 – By Drug Class (Antihistamines, Corticosteroids, Decongestants, Combination Drug, Antibiotics, Acid Blockers, Other Drug Classes), By Route Of Administration (Oral, Inhalational, Injectable, Other Route of Administrations), By End-Users (Hospitals, Homecare, Specialty Centers, Other End Users), By Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy) – Market Size, Trends, And Global Forecast 2024-2033
View Report
Respiratory Devices And Equipment (Therapeutic And Diagnostic) Global Market Report 2024 – By Type (Diagnostic devices, Therapeutic devices, Monitoring devices), By Therapeutic Devices (Humidifiers, Nebulizers, Oxygen concentrators, Positive Airway Pressure (PAP) Devices, Ventilators, Other Therapeutic Devices), By Diagnostic Devices (Spirometer, Polysomnographs, Peak Flow Meters), By Monitoring Devices (Pulse oximeters, Capnographs, Gas analyzers), By Application (Chronic Obstructive Pulmonary Disease (COPD), Asthma, Obstructive Sleep Apnea (OSA), Respiratory Distress Syndrome (RDS), Cystic Fibrosis, Pneumonia), By End User (Hospitals, Clinics, Homecare settings, Ambulatory service centers,) – Market Size, Trends, And Global Forecast 2024-2033
View Report
Respiratory Disposables Global Market Report 2024 – By Type (Masks, Tubes, Inhalers, Other Types), By Disease Indications (Asthma, Chronic Obstructive Pulmonary Disorder, Tuberculosis, Lung Cancer, Other Chronic Respiratory Diseases), By Application (Adult, Pediatric & Neonatal), By End User (Hospitals, Clinics, Ambulatory Care Centers, Other End Users) – Market Size, Trends, And Global Forecast 2024-2033
View Report
Respiratory Devices And Equipment (Diagnostic) Global Market Report 2024 – By Product (Instruments And Devices, Assays And Reagents), By Test Type (Traditional Diagnostic Tests, Mechanical Tests, Imaging Tests, Molecular Diagnostic Tests), By Disease Type (Chronic Obstructive Pulmonary Disease, Lung Cancer, Asthma, Tuberculosis, Other Diseases), By End User (Hospital/Clinical Laboratories, Physician Offices, Reference Laboratories, Other End Users) – Market Size, Trends, And Global Forecast 2024-2033
View Report
Respiratory Devices And Equipment (Therapeutic) Global Market Report 2024 – By Product (Nebulizers, Humidifiers, Oxygen Concentrators, Positive Airway Pressure Devices, Ventilators, Capnographs, Gas Analyzers), By Technology (HEPA Filter, Electrostatic Filtration, Microsphere Separation, Hollow Fiber Filtration, Other Technologies), By End-User (Homecare settings, Hospitals) – Market Size, Trends, And Global Forecast 2024-2033
View Report
Respiratory Monitoring Devices Global Market Report 2024 – By Type (Capnographs, Gas Analyzers, Pulse Oximeters, Peak Flow Meters, Spirometers, Polysomnographs, Others Types), By Application (Chronic Obstructive Pulmonary Disease (COPD), Infectious Diseases, Asthma, Other Applications), By End-User (Laboratories, Hospitals, Home Use) – Market Size, Trends, And Global Forecast 2024-2033
View Report

Frequently Asked Questions

What is the definition of the nontuberculous mycobacterial infection market?

A nontuberculous mycobacterial (NTM) infection is an infectious disease caused by various species of mycobacteria other than mycobacterium tuberculosis, which is responsible for tuberculosis (TB). The role of nontuberculous mycobacterial (NTM) infections is primarily related to their impact on human health and their interaction with the immune system. request a sample here

How will the nontuberculous mycobacterial infection market drivers and restraints affect the nontuberculous mycobacterial infection market dynamics? What forces will shape the nontuberculous mycobacterial infection industry going forward?

The nontuberculous mycobacterial infection market major growth driver - Rising Prevalence Of Copd Fuels Growth In The Nontuberculous Mycobacterial Infection Market. request a sample here

What is the forecast market size or the forecast market value of the nontuberculous mycobacterial infection market?

The nontuberculous mycobacterial infection market size has grown strongly in recent years. It will grow from $13.43 billion in 2023 to $14.25 billion in 2024 at a compound annual growth rate (CAGR) of 6.1%. The growth in the historic period can be attributed to improved diagnostics, aging population, cystic fibrosis awareness, immunosuppressive medications. The nontuberculous mycobacterial infection market size is expected to see strong growth in the next few years. It will grow to $18.17 billion in 2028 at a compound annual growth rate (CAGR) of 6.3%. The growth in the forecast period can be attributed to antimicrobial drug development, increasing ntm awareness, advances in genetic research, telehealth and remote monitoring. Major trends in the forecast period include personalized treatment, regulatory focus, combination therapies, digital health tools. request a sample here

How is the nontuberculous mycobacterial infection market segmented?

The nontuberculous mycobacterial infection market is segmented
1) By Drug Class: Macrolides, Rifampin, Aminoglycoside, Other Drug Classes
2) By Route Of Administration: Oral, Parenteral, Other Routes
3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online PharmaciesFor further insights on the nontuberculous mycobacterial infection market request a sample here

Which region has the largest share of the nontuberculous mycobacterial infection market? What are the other regions covered in the report?

North America was the largest region in the nontuberculous mycobacterial infection market in 2023. North America is expected to be the fastest-growing region in the forecast period. The regions covered in nontuberculous mycobacterial infection market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. request a sample here.

Who are the major players in the nontuberculous mycobacterial infection market?

Major players in the nontuberculous mycobacterial infection market are Pfizer Inc., Johnson & Johnson, F. Hoffman La Roche AG, Merck & Co. Inc., AbbVie Inc., Bayer AG, Novartis AG, Sanofi S.A., Bristol Myers Squibb, AstraZeneca PLC, Abbott Laboratories, GlaxoSmithKline PLC, Takeda Pharmaceutical Company, Eli Lilly and Company, C.H. Boehringer Sohn AG & Co. KG, Teva Pharmaceutical Industries Ltd., Mylan N.V., Astellas Pharma Inc., Vertex Pharmaceuticals Inc., Sun Pharmaceutical Industries Ltd., Horizon Therapeutics PLC, Lupin Limited, BioMarin Pharmaceutical Inc., Ionis Pharmaceuticals Inc., Insmed Incorporated, Paratek Pharmaceuticals Inc., Spero Therapeutics Inc., Aradigm Corporation, Dauntless Pharmaceuticals Inc., Validus Pharmaceuticals LLC. request a sample here.

What are the key trends in the nontuberculous mycobacterial infection market?

Major trend in the nontuberculous mycobacterial infection market - Adoption Of Innovative Treatment Approvals In The Nontuberculous Mycobacterial Infection Market. request a sample here.

What are the major opportunities in the nontuberculous mycobacterial infection market? What are the strategies for the nontuberculous mycobacterial infection market?

For detailed insights on the major opportunities and strategies in the nontuberculous mycobacterial infection market, request a sample here.

How does the nontuberculous mycobacterial infection market relate to the overall economy and other similar markets?

For detailed insights on nontuberculous mycobacterial infection market's relation to the overall economy and other similar markets, request a sample here.

What are the latest mergers and acquisitions in the nontuberculous mycobacterial infection industry?

For detailed insights on the mergers and acquisitions in the nontuberculous mycobacterial infection industry, request a sample here.

What are the key dynamics influencing the nontuberculous mycobacterial infection market growth? SWOT analysis of the nontuberculous mycobacterial infection market.

For detailed insights on the key dynamics influencing the nontuberculous mycobacterial infection market growth and SWOT analysis of the nontuberculous mycobacterial infection industry, request a sample here.